Akebia Therapeutics, Inc.
AKBA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001517022
In the last 90 days, Akebia Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 170 institutions reported holding it in 13F filings for Q2 2026, worth $123.2M in total; no superinvestor holds it.
Holders of 5% or more of AKBA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Akebia Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 6.10%15.1M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |
| State Street Corp | 13G | 5.20%13.7M shares | New | Feb 9, 20261 filing | Feb 9, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
5 Schedule 13D and 13G filings on Akebia Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 20263:24 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −5.37 ppfrom 5.37%Below 5% | Mar 13, 2026 | SEC |
| Feb 9, 20266:16 AM ET | State Street Corp | 13G | 5.20%13.7M shares | New | Dec 31, 2025 | SEC |
| Apr 30, 202510:57 AM ET | Vanguard Group Inc | 13G | 5.37%12.7M shares | New | Mar 31, 2025 | SEC |
| Apr 17, 20259:35 AM ET | BlackRock, Inc. | 13G/A | 6.10%15.1M shares | – | Mar 31, 2025 | SEC |
| Feb 14, 20255:00 PM ET | Satter Muneer A | 13G/A | 2.60%5.75M shares | –Below 5% | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Akebia Therapeutics, Inc. shares.
No Form 144 notices for Akebia Therapeutics, Inc. are on file.